✦ LIBER ✦

Tables for Statisticians and Biometricians

✍ Scribed by FISHER, R. A.

Book ID: 109503415
Publisher: Nature Publishing Group
Year: 1933
Tongue: English
Weight: 225 KB
Volume: 131
Category: Article
ISSN: 0028-0836
DOI: 10.1038/131893a0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Tables for Statisticians and Biometricia

Tables for Statisticians and Biometricians, Part II

✍ PEARSON, KARL 📂 Article 📅 1932 🏛 Nature Publishing Group 🌐 English ⚖ 105 KB

Tables for Statisticians

✍ WISHART, J. 📂 Article 📅 1939 🏛 Nature Publishing Group 🌐 English ⚖ 109 KB

Stereology for Statisticians

✍ Torsten Mattfeldt 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 41 KB

Nonparametric Statistics for Non-Statist

Nonparametric Statistics for Non-Statisticians (A Step-by-Step Approach) || Appendix B: Tables of Critical Values

✍ Corder, Gregory W.; Foreman, Dale I. 📂 Article 📅 2011 🏛 John Wiley & Sons, Inc. 🌐 English ⚖ 733 KB

**A practical and understandable approach to nonparametric statistics for researchers across diverse areas of study** As the importance of nonparametric methods in modern statistics continues to grow, these techniques are being increasingly applied to experimental designs across various fields of s

Criteria for authorship for statistician

Criteria for authorship for statisticians in medical papers

✍ Robert A. Parker; Nancy G. Berman 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB

We organize a statistician's potential scientific and intellectual contributions to a medical study into three types of activities relating to design, implementation and analysis. For each type, we describe high-level, mid-level and low-level contributions. Using this framework, we develop a point s

Issues for statisticians in pharmaco-eco

Issues for statisticians in pharmaco-economic evaluations

✍ A. P. Grieve 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB

Economic evaluations of new pharmaceutical products are of increasing importance to pharmaceutical companies. In this paper we investigate a number of topics of greater or lesser importance to statisticians who need to involve themselves in pharmaco-economic evaluations. These range from the need to